PathoGenesis
Executive Summary
Off-label promotion of Tobi aerosol administration for the treatment of bronchiectasis could begin following publication of Phase II trial data in 1999, PathoGenesis Chief Financial Officer Alan Meyer declared Oct. 6 at the Warburg Dillon Read conference in New York. "With FDA regulations for modernization...I think we have a good shot that once we have that Phase II data published, we're going to be able to promote that" indication. PathoGenesis has completed enrollment of the Phase II bronchiectasis trial as well as an early in-patient portion of the trial, Meyer noted. The drug, marketed in the U.S. for the management of Pseudomonas aeruginosa infections in cystic fibrosis patients, is also being studied as a potential lung sterilizer to prevent the spread of tuberculosis